FDA adcom documents may offer reasonable path for OIC drug class
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee (adcom) is slated to meet Wednesday to discuss the potential cardiovascular (CV) risk associated with peripherally acting opioid receptor antagonists in development to treat opioid-induced constipation (OIC).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST